J Arellano1, J M González2, Y Qian1, M Habib3, A F Mohamed3, F Gatta4, A B Hauber3, J Posner3, N Califaretti5, E Chow6. 1. Amgen, Thousand Oaks, CA, U.S.A.; 2. RTI Health Solutions, Research Triangle Park, NC, U.S.A.; 3. Amgen Canada, Toronto, ON; 4. Amgen Europe, Zug, Switzerland; 5. Grand River Regional Cancer Centre, Waterloo, ON; 6. Sunnybrook Health Sciences Centre, Toronto, ON.
Abstract
BACKGROUND: Currently in Canada, several bone-targeted agents (btas) with varying characteristics are available for the prevention of skeletal-related events (sres) in patients with bone metastasis secondary to solid tumours. In the present study, we evaluated the preferences of physicians in Canada for the various attributes of the available btas. METHODS: Physicians treating patients with bone metastasis from solid tumours were invited to complete an online discrete-choice experiment. Respondents were asked to choose between pairs of hypothetical medications for virtual patients. Each hypothetical medication was described based on predefined key attributes: time until first sre, time until worsening of pain, medication-related annual risk of osteonecrosis of the jaw (onj), medication-related annual risk of renal impairment, and mode of administration. A random-parameters logit model was used to analyze the choices between hypothetical medications and thus infer physician preferences for medication attributes. RESULTS: Responses from the 200 physicians who completed the discrete-choice experiment suggested that months until first sre, risk of renal impairment, and months until worsening of pain were considered the most important attributes affecting choice of bta. The annual risk of onj was considered the least important attribute. CONCLUSIONS: When making treatment decisions about the choice of bta for patients with bone metastasis from solid tumours, delaying sres and worsening of pain, and reducing the risk of renal impairment are primary considerations for physicians in Canada.
BACKGROUND: Currently in Canada, several bone-targeted agents (btas) with varying characteristics are available for the prevention of skeletal-related events (sres) in patients with bone metastasis secondary to solid tumours. In the present study, we evaluated the preferences of physicians in Canada for the various attributes of the available btas. METHODS: Physicians treating patients with bone metastasis from solid tumours were invited to complete an online discrete-choice experiment. Respondents were asked to choose between pairs of hypothetical medications for virtual patients. Each hypothetical medication was described based on predefined key attributes: time until first sre, time until worsening of pain, medication-related annual risk of osteonecrosis of the jaw (onj), medication-related annual risk of renal impairment, and mode of administration. A random-parameters logit model was used to analyze the choices between hypothetical medications and thus infer physician preferences for medication attributes. RESULTS: Responses from the 200 physicians who completed the discrete-choice experiment suggested that months until first sre, risk of renal impairment, and months until worsening of pain were considered the most important attributes affecting choice of bta. The annual risk of onj was considered the least important attribute. CONCLUSIONS: When making treatment decisions about the choice of bta for patients with bone metastasis from solid tumours, delaying sres and worsening of pain, and reducing the risk of renal impairment are primary considerations for physicians in Canada.
Authors: Deborah Marshall; John F P Bridges; Brett Hauber; Ruthanne Cameron; Lauren Donnalley; Ken Fyie; F Reed Johnson Journal: Patient Date: 2010-12-01 Impact factor: 3.883
Authors: Thomas Delea; Corey Langer; James McKiernan; Martin Liss; John Edelsberg; Jane Brandman; Jennifer Sung; Monika Raut; Gerry Oster Journal: Oncology Date: 2004 Impact factor: 2.935
Authors: John F P Bridges; A Brett Hauber; Deborah Marshall; Andrew Lloyd; Lisa A Prosser; Dean A Regier; F Reed Johnson; Josephine Mauskopf Journal: Value Health Date: 2011-04-22 Impact factor: 5.725
Authors: A Agrillo; F Filiaci; V Ramieri; E Riccardi; D Quarato; C Rinna; P Gennaro; F Cascino; V Mitro; C Ungari Journal: Eur Rev Med Pharmacol Sci Date: 2012-11 Impact factor: 3.507
Authors: Alysa Fairchild; Elizabeth Barnes; Sunita Ghosh; Edgar Ben-Josef; Daniel Roos; William Hartsell; Tanya Holt; Jackson Wu; Nora Janjan; Edward Chow Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-21 Impact factor: 7.038
Authors: Allan Lipton; Karim Fizazi; Alison T Stopeck; David H Henry; Janet E Brown; Denise A Yardley; Gary E Richardson; Salvatore Siena; Pablo Maroto; Michael Clemens; Boris Bilynskyy; Veena Charu; Philippe Beuzeboc; Michael Rader; Maria Viniegra; Fred Saad; Chunlei Ke; Ada Braun; Susie Jun Journal: Eur J Cancer Date: 2012-09-10 Impact factor: 9.162
Authors: F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey Journal: Ann Oncol Date: 2011-10-10 Impact factor: 32.976
Authors: Yi Qian; Jorge Arellano; Francesca Gatta; Guy Hechmati; A Brett Hauber; Ateesha F Mohamed; Amit Bahl; Roger von Moos; Jean-Jacques Body Journal: BMC Health Serv Res Date: 2018-07-03 Impact factor: 2.655
Authors: Dionna Jacobson; Benoit Cadieux; Celestia S Higano; David H Henry; Basia A Bachmann; Marko Rehn; Alison T Stopeck; Hossam Saad Journal: J Bone Oncol Date: 2022-03-17 Impact factor: 4.072
Authors: Jamie L Welshhans; Jeffrey J Harmon; Ira Papel; Richard Gentile; Devinder Mangat; Patrick Byrne; Ryan M Collar Journal: JAMA Facial Plast Surg Date: 2018-03-01 Impact factor: 4.611